Reply to: "Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood"
- PMID: 35587632
- DOI: 10.1002/mds.29003
Reply to: "Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood"
Comment on
-
Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood.Mov Disord. 2021 Nov;36(11):2675-2681. doi: 10.1002/mds.28749. Epub 2021 Aug 16. Mov Disord. 2021. PMID: 34397117
-
Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood.Mov Disord. 2022 May;37(5):1120-1121. doi: 10.1002/mds.29008. Mov Disord. 2022. PMID: 35587620 No abstract available.
Similar articles
-
Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood.Mov Disord. 2022 May;37(5):1120-1121. doi: 10.1002/mds.29008. Mov Disord. 2022. PMID: 35587620 No abstract available.
-
Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood.Mov Disord. 2021 Nov;36(11):2675-2681. doi: 10.1002/mds.28749. Epub 2021 Aug 16. Mov Disord. 2021. PMID: 34397117
-
The Ratio of Expanded to Normal Ataxin 3 in Peripheral Blood Mononuclear Cells Correlates with the Age at Onset in Spinocerebellar Ataxia Type 3.Mov Disord. 2022 May;37(5):1098-1099. doi: 10.1002/mds.28962. Epub 2022 Mar 12. Mov Disord. 2022. PMID: 35278005 No abstract available.
-
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480. NeuroRx. 2005. PMID: 16389311 Free PMC article. Review.
-
Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.Adv Exp Med Biol. 2020;1233:237-260. doi: 10.1007/978-3-030-38266-7_10. Adv Exp Med Biol. 2020. PMID: 32274760 Review.
References
-
- Hubener-Schmid J, Kuhlbrodt K, Peladan J, et al. Polyglutamine-expanded Ataxin-3: a target engagement marker for spinocerebellar ataxia type 3 in peripheral blood. Mov Disord 2021;36(11):2675-2681.
-
- Prudencio M, Garcia-Moreno H, Jansen-West KR, et al. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Sci Transl Med 2020;12(566):eabb7086
-
- Miller J, Arrasate M, Brooks E, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol 2011;7(12):925-934.
-
- Klein FAC, Zeder-Lutz G, Cousido-Siah A, et al. Linear and extended: a common polyglutamine conformation recognized by three antibodies MW1, 1C2 and 3B5H10. Hum Mol Genet 2013;22(20):4215-4223.
-
- Owens EG, New DM, West AP Jr, Bjorkman PJ. Anti-PolyQ antibodies recognize a short polyQ stretch in both normal and mutant huntingtin exon 1. J Mol Biol 2015;427(15):2507-2519.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources